Skip to main content
ANAB
NASDAQ Life Sciences

AnaptysBio Swings to $176.4M Net Income in Transition Period on $181.5M Tax Benefit

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Biotech Stocks · Healthcare
Sentiment info
Positive
Importance info
8
Price
$55.99
Mkt Cap
$1.626B
52W Low
$13.658
52W High
$72.36
52W Position info
310% above low
Off High info
23% below high
Rel. Volume info
0.8× avg
Market data snapshot near publication time

ANAB has more than doubled off its 52-week low of $13.658.

Summary

AnaptysBio's transition report shows $176.4M net income from continuing operations, driven by a $181.5M tax benefit, and formally documents the completed Spin-Off of First Tracks Biotherapeutics.


Key Events · Earnings and Guidance · ANAB

  • Transition Period Net Income

    Net income from continuing operations was $176.4 million for the six months ended June 30, 2026, compared to $16.6 million in the prior year period.

  • Tax Benefit Drives Profitability

    A $181.5 million income tax benefit resulted from releasing a valuation allowance on deferred tax assets, reflecting expected future profits from the royalty business.

  • Spin-Off Completed

    First Tracks Biotherapeutics was spun off on April 20, 2026, with 29.1 million shares distributed pro rata and $100 million in cash allocated to the new entity.

  • Cash Position

    Cash, cash equivalents, and investments totaled $164.1 million as of June 30, 2026, down from $211.6 million at December 31, 2025.


Analysis · ANAB · Life Sciences

The first 10-KT following AnaptysBio's fiscal year change reveals a dramatic swing to profitability from continuing operations, with net income of $176.4 million for the six months ended June 30, 2026. Almost the entire result stems from a $181.5 million non-cash income tax benefit from releasing a valuation allowance on deferred tax assets, reflecting management's expectation of future profits from the retained royalty business. The filing also formally documents the completed Spin-Off of First Tracks Biotherapeutics, which distributed 29.1 million shares and $100 million in cash, leaving AnaptysBio as a lean royalty management company with $164.1 million in cash and investments. The ongoing GSK litigation remains a key risk, with post-trial argument scheduled for October 20, 2026.

How filings like this one have moved

In the 30 days to Nov 15, 2026, 48.2% of the 1980 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.20%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, ANAB was trading at $55.99 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1.6B. The 52-week trading range was $13.66 to $72.36. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

ANAB - Latest Insights

ANAB
Nov 12, 2026, 4:21 PM EST
Filing Type: 10-Q
Importance Score:
7
Price at Filing: $47.77
Real-time Price: $46.25 info
Change: -$1.52 (-3%) info
Market Cap: $1.375B info
ANAB
Nov 12, 2026, 4:16 PM EST
Source: Reuters
Importance Score:
7
Price at Filing: $47.77
Real-time Price: $46.25 info
Change: -$1.52 (-3%) info
Market Cap: $1.375B info
ANAB
Oct 20, 2026, 3:49 PM EDT
Source: Seeking Alpha
Importance Score:
7
Price at Filing: $45.00
Real-time Price: $46.25 info
Change: +$1.25 (+3%) info
Market Cap: $1.375B info
ANAB
Oct 19, 2026, 2:18 PM EDT
Source: GlobeNewswire
Importance Score:
8
Price at Filing: $49.23
Real-time Price: $46.25 info
Change: -$2.98 (-6%) info
Market Cap: $1.375B info
ANAB
Sep 28, 2026, 7:00 AM EDT
Source: Wiseek News
Importance Score:
8
Price at Filing: $50.85
Real-time Price: $46.25 info
Change: -$4.60 (-9%) info
Market Cap: $1.375B info